WooGene B&G Co. Ltd (018620) - Total Liabilities

Latest as of September 2025: ₩50.21 Billion KRW ≈ $34.03 Million USD

Based on the latest financial reports, WooGene B&G Co. Ltd (018620) has total liabilities worth ₩50.21 Billion KRW (≈ $34.03 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore WooGene B&G Co. Ltd (018620) investment intensity to see how much of total assets are deployed in long-term investments.

WooGene B&G Co. Ltd - Total Liabilities Trend (2011–2024)

This chart illustrates how WooGene B&G Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see WooGene B&G Co. Ltd assets under control.

WooGene B&G Co. Ltd Competitors by Total Liabilities

The table below lists competitors of WooGene B&G Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Asian Phytoceuticals Public Company Limited
BK:APCO
Thailand ฿69.91 Million
City Sports and Recreation Public Company Limited
BK:CSR
Thailand ฿149.14 Million
Cs Holdings
KO:000590
Korea ₩31.86 Billion
Sam Jung Pulp
KO:009770
Korea ₩31.23 Billion
Workpoint Entertainment Public Company Limited
BK:WORK
Thailand ฿638.71 Million
Genie Music Corporation
KQ:043610
Korea ₩115.36 Billion
Tadmax Resources Berhad
KLSE:4022
Malaysia RM638.61 Million
CTI Traffic Industries Co Ltd
TWO:2230
Taiwan NT$695.62 Million

Liability Composition Analysis (2011–2024)

This chart breaks down WooGene B&G Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is WooGene B&G Co. Ltd's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.23 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.80 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.43 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how WooGene B&G Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for WooGene B&G Co. Ltd (2011–2024)

The table below shows the annual total liabilities of WooGene B&G Co. Ltd from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 ₩85.08 Billion
≈ $57.66 Million
+72.74%
2023-12-31 ₩49.25 Billion
≈ $33.38 Million
-12.37%
2022-12-31 ₩56.20 Billion
≈ $38.09 Million
+23.90%
2021-12-31 ₩45.36 Billion
≈ $30.74 Million
-4.93%
2020-12-31 ₩47.72 Billion
≈ $32.34 Million
-17.54%
2019-12-31 ₩57.87 Billion
≈ $39.22 Million
+72.55%
2018-12-31 ₩33.54 Billion
≈ $22.73 Million
-10.80%
2017-12-31 ₩37.60 Billion
≈ $25.48 Million
+4.42%
2016-12-31 ₩36.01 Billion
≈ $24.40 Million
+77.05%
2015-12-31 ₩20.34 Billion
≈ $13.78 Million
+142.38%
2014-12-31 ₩8.39 Billion
≈ $5.69 Million
+10.11%
2012-12-31 ₩7.62 Billion
≈ $5.16 Million
-5.51%
2011-12-31 ₩8.06 Billion
≈ $5.47 Million
--

About WooGene B&G Co. Ltd

KQ:018620 Korea Pharmaceuticals
Market Cap
$47.07 Million
₩69.46 Billion KRW
Market Cap Rank
#22205 Global
#1393 in Korea
Share Price
₩2675.00
Change (1 day)
+0.19%
52-Week Range
₩670.00 - ₩3400.00
All Time High
₩6913.04
About

WooGene B&G Co., Ltd. develops, manufactures, and markets products to animal health and livestock industry in South Korea and internationally. The company's products include veterinary medicines, raw materials, and probiotic. It offers veterinary medicines for poultry, swine, bovine, horse, dog, cat, sheep, deer, and aquaculture markets; and vaccines for swine, poultry, canine, and cow markets. T… Read more